Discovery of 4‐(isopentyloxy)‐3‐nitrobenzamide derivatives as xanthine oxidase inhibitors through a non‐anthraquinone exploration
Archiv der Pharmazie · 2024
DOI: 10.1002/ardp.202400137 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Shuai Guo und 13 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy/Key Laboratory of Research and Development of Small Molecule Targeted Antitumor Drugs, China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Xanthine Oxidase, Enzyme Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Young Talents Program of China Medical University.
Abstract (Originalsprache)
In our previous study, we reported a series of N ‐(9,10‐anthraquinone‐2‐carbonyl) amino acid derivatives as novel inhibitors of xanthine oxidase (XO). Recognizing the suboptimal drug‐like properties associated with the anthraquinone moiety, we embarked on a nonanthraquinone medicinal chemistry exploration in the current investigation. Through systematic structure–activity relationship (SAR) studies, we identified a series of 4‐(isopentyloxy)‐3‐nitrobenzamide derivatives exhibiting excellent in vitro potency against XO. The optimized compound, 4‐isopentyloxy‐ N ‐(1 H ‐pyrazol‐3‐yl)‐3‐nitrobenzamide ( 6k ), demonstrated exceptional in vitro potency with an IC 50 value of 0.13 μM. Compound 6k showed favorable drug‐like characteristics with ligand efficiency (LE) and lipophilic ligand efficiency (LLE) values of 0.41 and 3.73, respectively. In comparison to the initial compound 1d , 6k exhibited a substantial 24‐fold improvement in IC 50 , along with a 1.6‐fold enhancement in LE and a 3.7‐fold increase in LLE. Molecular modeling studies provided insights into the strong interactions of 6k with critical amino acid residues within the active site. Furthermore, in vivo hypouricemic investigations convincingly demonstrated that 6k significantly reduced serum uric acid levels in rats. The MTT results revealed that compound 6k is nontoxic to healthy cells. The gastric and intestinal stability assay demonstrated that compound 6k exhibits good stability in the gastric and intestinal environments. In conclusion, compound 6k emerges as a promising lead compound, showcasing both exceptional in vitro potency and favorable drug‐like characteristics, thereby warranting further exploration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy/Key Laboratory of Research and Development of Small Molecule Targeted Antitumor Drugs, China Medical University, Shenyang, China.
Förderung
- National Natural Science Foundation of China
- Young Talents Program of China Medical University
Zitieren
APA
Guo, S., Sun, Q., Zhang, X., Li, S. Y., Liu, H. Y., Ge, G. H., Wang, J., Liu, X. Y., Xu, B., Li, T. T., Zhou, X. F., Wang, Y. P., Meng, F. H., & Zhang, T. J. (2024). Discovery of 4‐(isopentyloxy)‐3‐nitrobenzamide derivatives as xanthine oxidase inhibitors through a non‐anthraquinone exploration. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400137
Vancouver
Guo S, Sun Q, Zhang X, Li SY, Liu HY, Ge GH, et al. Discovery of 4‐(isopentyloxy)‐3‐nitrobenzamide derivatives as xanthine oxidase inhibitors through a non‐anthraquinone exploration. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202400137
BibTeX
@article{Guo2024,
author = {Guo, Shuai and Sun, Qi and Zhang, Xu and Li, Song-Ye and Liu, Hong-Ye and Ge, Gong-Hui and Wang, Jing and Liu, Xing-Yang and Xu, Ben and Li, Ting-Ting and Zhou, Xian-Feng and Wang, Yan-Ping and Meng, Fan-Hao and Zhang, Ting-Jian},
title = {Discovery of 4‐(isopentyloxy)‐3‐nitrobenzamide derivatives as xanthine oxidase inhibitors through a non‐anthraquinone exploration},
journal = {Archiv der Pharmazie},
year = {2024},
doi = {10.1002/ardp.202400137}
}
EUVIMED